Biotech IPOs get their groove back | PitchBook News Summary

1. Key Themes

Theme 1: Biotech Is the Defensive Hedge to AI Bubble Risk

Crossover investors and generalist asset managers are rotating out of over-indexed AI/tech positions and back into biopharma as a diversification play. The IPO window is reopening with conviction — deals are not just getting done, they're getting upsized.

"Understandably so, tech and AI companies have become such a large part of major generalist indices, in some cases probably overweight. Now there seems to be a little bit of a pivot back." — Kevin Eisele, Head of Biotech Capital Markets, William Blair

"Biopharma IPOs this year have been consistently upsized thanks to a resurgence in investor interest: Kailera's April IPO far surpassed its $500 million target. Avalyn's listing later that month raised more than $100 million above expectations."

"There were more exits in Q1 than in any quarter since Q4 2021, at the tail end of the pandemic-era boom."

Theme 2: GLP-1 Cash Fueling Pharma M&A — Creating a Biotech Liquidity Cycle

Big pharma, flush with GLP-1 revenues, is aggressively restocking pipelines via acquisition. This is creating a compelling and near-term liquidity pathway for VC-backed biotech companies, making biopharma more investable on both the upside (M&A exits) and the downside (defensive demand).

"Pharmaceutical acquirers are flush with cash from the GLP-1 drug boom and are looking for the next generation of superstars to refill their pipelines. So far in 2026, Eli Lilly alone has announced acquisitions worth more than $20 billion, including two of its biggest deals ever: Centessa Pharmaceuticals, which it bought for $7.8 billion, and Kelonia Therapeutics, for $7 billion."

Theme 3: AI Is Concentrating Capital — Not Democratizing It — in Cybersecurity

The headline "early-stage VC surpasses late-stage in cybersecurity" is misleading. Overall deal count is at its lowest since 2018. What's actually happening is a narrow band of AI-native startups are pulling in enormous, late-stage-scale checks at the Series A/B level — inflating early-stage aggregate numbers without a broad-based revival.

"This flip isn't a broad revival of early-stage dealmaking. With the overall quarterly deal count at its lowest level since 2018, capital is increasingly concentrated in fewer startups."

"Early-stage is generating late-stage-esque capital simply because more are willing to pay an AI premium." — Dimitri Zabelin, Senior Research Analyst, PitchBook

"The $2.1 billion was deployed across 60 deals, while late-stage VC funding hit $1.7 billion across 70 deals."

Theme 4: Venture Secondaries Are Becoming Core Market Infrastructure

Venture secondaries have scaled from a niche liquidity workaround to a legitimate exit channel on par with acquisitions and IPOs — a structural market shift with significant implications for LP liquidity and VC portfolio management.

"In 2025, venture secondaries reached $106.3 billion in transaction value, elevating them from niche liquidity workaround to core venture market infrastructure. With increasing institutional adoption, they are quickly scaling to the same level as acquisitions and IPOs, potentially setting a new standard for the space."

Theme 5: PE Is Going Risk-Off, Pivoting from SaaS to Physical Infrastructure

Public private equity managers are quietly de-risking, reassessing SaaS exposure and underwriting assumptions, and rotating toward physical infrastructure. This signals a broader valuation reckoning in enterprise software.

"Public PE players are quietly going into risk-off mode. As managers triage their SaaS exposure and reassess underwriting assumptions, a pivot to physical infrastructure is underway."

2. Contrarian Perspectives

Perspective 1: The Cybersecurity "Early-Stage Revival" Is a Statistical Mirage

The conventional read is that early-stage cybersecurity VC is surging. The contrarian truth: it's a few mega-rounds by AI-branded startups distorting aggregate figures while total deal volume collapses to multi-year lows. Investors chasing the trend at scale may be buying into a crowded, inflated narrow cohort rather than a broad recovery.

"With the overall quarterly deal count at its lowest level since 2018, capital is increasingly concentrated in fewer startups." "Tenex.AI...raised a $250 million Series B...Upwind, a cloud security startup, announced an up-sized Series B in January, netting $250 million." Both became unicorns at Series B — structurally unusual and driven by AI premium pricing, not broad market strength.

Perspective 2: Biotech Is "Defensive" but Not Immune — the Risk Is Underappreciated

The consensus is forming that biotech is a safe harbor from AI bubble risk. The more nuanced view is that a severe AI correction could still have sweeping contagion effects on biopharma, particularly if crossover investors — the same cohort now rebalancing into biotech — need to raise cash.

"I hesitate to say totally immune, but certainly it's a much more defensive segment of the market. The sad reality is that patients are always getting sick and are always going to need therapies." — Kevin Eisele, William Blair

"A severe correction in the bubbling AI tech market could have sweeping impacts. So far, modest tumult has left it unaffected." — The qualifier "severe" is doing significant work here; modest volatility has been absorbed, but tail risk remains.

Perspective 3: The AI "Tax" on Enterprise Budgets Is a Governance Failure, Not Just a Spend Signal

One company reportedly spent $500 million on Claude tokens in a single month after failing to set employee usage limits. This is being reported as evidence of voracious AI appetite, but it equally signals that enterprise AI governance and cost controls are dangerously immature — creating risk for both AI vendors dependent on unsustainable consumption and enterprises without spend guardrails.

"One company spent $500 million on Claude tokens in a single month after forgetting to set employee limits." — Axios, cited in the newsletter.

3. Companies Identified

Kailera

Description: Biopharma company; recently completed an IPO
Why mentioned: Cited as evidence of resurgent biopharma IPO momentum; its offering "far surpassed its $500 million target"
Quote: "Kailera's April IPO far surpassed its $500 million target."

Avalyn

Description: Biopharma company; recently completed an IPO
Why mentioned: Further proof of upsized biopharma listings
Quote: "Avalyn's listing later that month raised more than $100 million above expectations."

Eli Lilly

Description: Global pharmaceutical giant
Why mentioned: Case study in GLP-1-fueled M&A activity; most active acquirer in biopharma in 2026
Quote: "Eli Lilly alone has announced acquisitions worth more than $20 billion, including two of its biggest deals ever: Centessa Pharmaceuticals, which it bought for $7.8 billion, and Kelonia Therapeutics, for $7 billion."

Centessa Pharmaceuticals

Description: Drug development company
Why mentioned: Acquired by Eli Lilly for $7.8 billion; example of large M&A exit for VC-backed biotech
Quote: "Centessa Pharmaceuticals, which it bought for $7.8 billion."

Tenex.AI

Description: AI-enabled cybersecurity threat detection startup
Why mentioned: Raised a $250M Series B; became a unicorn; exemplifies outsized AI-premium rounds at early stage
Quote: "Tenex.AI, which offers AI-enabled threat detection software, said in March it had raised a $250 million Series B led by Crosspoint Capital Partners."

Upwind

Description: Cloud security startup
Why mentioned: Raised an upsized $250M Series B; became a unicorn at $1.5B valuation
Quote: "Upwind, a cloud security startup, announced an up-sized Series B in January, netting $250 million led by Bessemer Venture Partners."

Gray Swan

Description: Pittsburgh-based AI security and safety startup
Why mentioned: Raised a $40M Series A; named in newsletter headline
Quote: "Pittsburgh-based Gray Swan, an AI security and safety startup, raised a $40 million Series A led by Wing Venture Capital and Madrona."

Geordie AI

Description: London-based security and governance platform for AI agents
Why mentioned: Raised a $30M Series A; operates in the emerging AI agent governance space
Quote: "Geordie AI, a London-based developer of a security and governance platform for AI agents, secured a $30 million Series A led by Balderton Capital."

Base Power

Description: Home battery startup
Why mentioned: Reportedly in talks to raise at a $12 billion valuation — a remarkable figure for a hardware energy startup
Quote: "Home battery startup Base Power is in talks to raise a round led by Ribbit Capital at a $12 billion valuation."

Anthropic

Description: AI lab (maker of Claude)
Why mentioned: Center of a $36B debt financing deal involving Apollo and Blackstone to fund chip purchases from Google
Quote: "Apollo Global Management and Blackstone are working on a $36 billion debt financing deal to help purchase chips from Google for use in Anthropic's AI infrastructure."

MaintainX

Description: Maintenance tools/operations software company; Bessemer-backed
Why mentioned: Agreed to be acquired by Autodesk for $3.6 billion — a notable VC exit
Quote: "Bessemer Venture Partners-backed MaintainX, a maintenance tools company, agreed to be acquired by Nasdaq-listed Autodesk in a $3.6 billion deal."

Entrata

Description: Property management software developer; Silver Lake-backed
Why mentioned: Filed for IPO; a signal of continued software liquidity
Quote: "Entrata, a property management software developer backed by Silver Lake, filed for an IPO."

Inherent

Description: London-based AI lab
Why mentioned: Raised a $50 million seed round — an unusually large seed — led by Index Ventures and Radical Ventures
Quote: "London-based AI lab Inherent raised a $50 million seed investment led by Index Ventures and Radical Ventures."

Picogrid

Description: Defense tech company building integration software for military systems
Why mentioned: Raised a $45M Series A from Bessemer; represents the defense tech VC trend
Quote: "Picogrid, a defense tech company building integration software for military systems, secured a $45 million Series A led by Bessemer Venture Partners."

4. People Identified

Kevin Eisele

Description: Head of Biotech Capital Markets Group, William Blair (investment bank)
Why mentioned: Primary expert voice on the biopharma IPO recovery and investor rotation thesis
Quote: "I hesitate to say totally immune, but certainly it's a much more defensive segment of the market. The sad reality is that patients are always getting sick and are always going to need therapies."

Dimitri Zabelin

Description: Senior Research Analyst, PitchBook
Why mentioned: Provides analytical framing for the cybersecurity VC concentration dynamic and M&A exit thesis
Quote: "Later-stage and venture growth funding rounds continue to dominate the cybersecurity landscape...Early-stage is generating late-stage-esque capital simply because more are willing to pay an AI premium."

Rosie Bradbury

Description: Senior Venture Capital Reporter, PitchBook
Why mentioned: Author of the biotech IPO feature article

Jacob Robbins

Description: Technology Reporter, PitchBook
Why mentioned: Author of the cybersecurity AI investment feature

5. Operating Insights

Insight 1: AI Spend Without Governance Is a Material Business Risk

The anecdote of a company inadvertently spending $500M on Claude tokens in a single month because it forgot to set employee limits is a direct warning for operators deploying AI tools at scale. Enterprises need usage controls, budget caps, and AI cost governance frameworks as a baseline operational requirement before broad internal deployment.

"One company spent $500 million on Claude tokens in a single month after forgetting to set employee limits."

Insight 2: In Cybersecurity, Slapping "AI" on Your Product Is Table Stakes for Fundraising — But Deals Are Thinning

For founders in the cybersecurity space, the funding environment is bifurcating sharply. AI-native positioning unlocks access to outsized early rounds; non-AI-native companies are increasingly shut out as overall deal count hits multi-year lows. The operating implication: differentiation must be built on genuine AI capability, not just labeling, as investor scrutiny will intensify when the premium normalizes.

"Median early-stage deal value climbed to $25 million in Q1 — above its 2025 level — while later-stage median figures remained flat...For companies so early in their lifecycle, these rounds are unusual but reflect a broader trend of AI-native startups attracting investor attention and capital."

Insight 3: Biotech Founders Should Accelerate IPO Prep — The Window Is Open But Correlated Risk Remains

The biopharma IPO window is open and investors are receptive. However, the primary driver of this reallocation is portfolio rebalancing away from AI/tech — meaning the window could narrow if a major AI market correction triggers broad risk-off behavior. Founders with clinical traction should move with urgency.

"Investors are also motivated by promising opportunities for liquidity...long-awaited liquidity events are expected to further drive confidence in VC-backed biotech deals." "A severe correction in the bubbling AI tech market could have sweeping impacts."

6. Overlooked Insights

Insight 1: Molecular Glue Could Be Biopharma's Next Breakout Therapeutic Category

Buried in the "Side Letters" section is a structurally significant scientific development: molecular glue technology can target approximately 80% of human proteins that traditional small-molecule drugs cannot reach — a massive addressable market expansion for pharma. Novartis, Roche, and Eli Lilly have already committed billions. This is early-stage but could rival GLP-1 in investment cycle significance.

"About 80% of proteins in the human body are too slippery for traditional pills to target. Molecular glue is changing that, and Novartis, Roche, and Lilly have already committed billions to chase it."

Insight 2: Africa VC Is Thinning but Remaining Investors Are Writing Bigger Checks — A Contrarian Entry Signal

The pullback of foreign investors from African VC is framed as a headwind, but the simultaneous observation that remaining investors are "writing bigger checks" suggests a flight-to-quality dynamic, not wholesale abandonment. For investors with local expertise or established relationships, reduced competition combined with larger check sizes may represent an attractive entry point.

"Foreign VCs are pulling back from Africa's startup ecosystem, and local funds are stretched thin — yet the investors who do show up are writing bigger checks."